C-reactive protein triggers inflammatory responses partly via TLR4/IRF3/NF-κB signaling pathway in rat vascular smooth muscle cells

Life Sciences

Volumn 87, Issue 11-12, 2010, Pages 367-374

  Liu, Na ^a   Liu, Jun Tian ^a   Ji, Yuan Yuan ^a   Lu, Pei Pei ^a  

^a MEDICAL SCHOOL OF XI AN JIAOTONG UNIVERSITY   (China)

Author keywords

Atherosclerosis; C reactive protein; Inflammation; Toll like receptor 4; Vascular smooth muscle cell

Indexed keywords

C REACTIVE PROTEIN; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERLEUKIN 6; MESSENGER RNA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TOLL LIKE RECEPTOR 4; I KAPPA B; LIPOPOLYSACCHARIDE; NF-KAPPAB INHIBITOR ALPHA; POLYMYXIN B; PROLINE; PROLINEDITHIOCARBAMATE; SMALL INTERFERING RNA; THIOCARBAMIC ACID DERIVATIVE; TLR4 PROTEIN, RAT;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; REAL TIME POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CELL CULTURE; CHEMICALLY INDUCED; CYTOLOGY; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; SMOOTH MUSCLE FIBER; SPRAGUE DAWLEY RAT;

ANIMALS; C-REACTIVE PROTEIN; CELLS, CULTURED; GENE EXPRESSION REGULATION; HUMANS; I-KAPPA B PROTEINS; INFLAMMATION; INTERFERON REGULATORY FACTOR-3; INTERLEUKIN-6; LIPOPOLYSACCHARIDES; MALE; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NF-KAPPA B; PHOSPHORYLATION; POLYMYXIN B; PPAR GAMMA; PROLINE; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; THIOCARBAMATES; TOLL-LIKE RECEPTOR 4;

RATTUS;

EID: 77956398080     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2010.07.012     Document Type: Article

References (48)

1. Baggio G., Donazzan S., Monti D., Mari D., Martini S., Gabelli C., Dalla Vestra M., Previato L., Guido M., Pigozzo S., Cortella I., Crepaldi G., Franceschi C. Lipoprotein (α) and lipoprotein profile in healthy centenarians: a reappraisal of vascular risk factors. The FASEB Journal 1998, 12(6):433-437.
2. Beutler B. Inferences, questions and possibilities in Toll-like receptor signaling. Nature 2004, 430(6996):257-263.
3. Bisoendial R.J., Kastelein J.J.P., Levels J.H.M., Zwaginga J.J., van den Bogaard B., Reitsma P.H., Meijers J.C.M., Hartman D., Levi M., Stroes E.S.G. Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circulation Research 2005, 96(7):714-716.
4. Calabró P., Willerson J.T., Yeh E.T.H. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 2003, 108(16):1930-1932.
5. de Beer F.C., Baltz M.L., Munn E.A., Feinstein A., Taylor J., Bruton C., Clamp J.R., Pepys M.B. Isolation and characterization of C-reactive protein and serum amyloid P component in the rat. Immunology 1982, 45(1):55-70.
6. Duval C., Chinetti G., Trottein F., Fruchart J.C., Staels B. The role of PPARs in atherosclerosis. Trends in Molecular Medicine 2002, 8(9):422-430.
7. Edfeldt K., Swedenborg J., Hansson G.K., Yan Z.Q. Expression of toll-like receptors in human atherosclerotic lesions: a possible pathway for plaque activation. Circulation 2002, 105(10):1158-1161.
8. Eisenhardt S.U., Habersberger J., Murphy A., Chen Y.C., Woollard K.J., Bassler N., Qian H., von Zur Muhlen C., Hagemeyer C.E., Ahrens I., Chin-Dusting J., Bobik A., Peter K. Dissociation of pentameric to monomeric C-reactive protein on activated platelets localizes inflammation to atherosclerotic plaques. Circulation Research 2009, 105(2):128-137.
9. Faure E., Equils O., Sieling P.A., Thomas L., Zhang F.X., Kirschning C.J., Polentarutti N., Muzio M., Arditi M. Bacterial lipopolysaccharide activates NF-κB through toll-like receptor 4 (TLR-4) in cultured human dermal endothelial cells: differential expression of TLR-4 and TLR-2 in endothelial cells. Journal of Biological Chemistry 2000, 275(15):11058-11063.
10. Frantz S., Ertl G., Bauersachs J. Mechanisms of disease: Toll-like receptors in cardiovascular disease. Nature Clinical Practice Cardiovascular Medicine 2007, 4(8):444-454.
11. Ghosh S., Karin M. Missing pieces in the NF-κB puzzle. Cell 2002, 109(2):S81-S96.
12. Gill R., Kemp J.A., Sabin C., Pepys M.B. Human C-reactive protein increases cerebral infarct size after middle cerebral artery occlusion in adult rats. Journal of Cerebral Blood Flow and Metabolism 2004, 24(11):1214-1218.
13. Griselli M., Herbert J., Hutchinson W.L., Taylor K.M., Sohail M., Krausz T., Pepys M.B. C-reactive protein and complement are important mediators of tissue damage in acutemyocardial infarction. Journal of Experimental Medicine 1999, 190(12):1733-1739.
14. Han K.J., Su X., Xu L.G., Bin L.H., Zhang J., Shu H.B. Mechanisms of the TRIF-induced interferon-stimulated response element and NF-κB activation and apoptosis pathways. Journal of Biological Chemistry 2004, 279(15):15652-15661.
15. Hattori Y., Matsumura M., Kasai K. Vascular smooth muscle cell activation by C-reactive protein. Cardiovascular Research 2003, 58(1):186-195.
16. Ikeda U., Ikeda M., Seino Y., Takahashi M., Kano S., Shimada K. Interleukin-6 gene transcripts are expressed in atherosclerotic lesions of genetically hyperlipidemic rabbits. Atherosclerosis 1992, 92(2-3):213-218.
17. Ji Y.Y., Liu J.T., Wang Z.D., Liu N. Angiotensin II induces inflammatory response partly via toll-like receptor 4-dependent signaling pathway in vascular smooth muscle cells. Cellular Physiology and Biochemistry 2009, 23(4-6):265-276.
18. Kaptoge S., Di Angelantonio E., Lowe G., Pepys M.B., Thompson S.G., Collins R., Danesh J. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis. Lancet 2010, 375(9709):132-140.
19. Lagrand W.K., Visser C.A., Hermens W.T., Niessen H.W., Verheugt F.W., Wolbink G.J., Hack C.E. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon?. Circulation 1999, 100(1):96-102.
20. Li H., He Y., Zhang J., Sun S., Sun B. Lipopolysaccharide regulates Toll-like receptor 4 expression in human aortic smooth muscle cells. Cell Biology International 2007, 31(8):831-835.
21. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation 2002, 105(9):1135-1143.
22. Marx N., Duez H., Fruchart J.C., Staels B. Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circulation Research 2004, 94(9):1168-1178.
23. Medzhitov R., Preston-Hurlburt P., Janeway C.A. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388(6640):394-397.
24. Michelsen K.S., Doherty T.M., Shah P.K., Arditi M. TLR signaling: an emerging bridge from innate immunity to atherogenesis. Journal of Immunology 2004, 173(10):5901-5907.
25. Navarro L., David M. p38-dependent activation of interferon regulatory factor 3 by lipopolysaccharide. Journal of Biological Chemistry 1999, 274(50):35535-35538.
26. Ogawa S., Lozach J., Benner C., Pascual G., Tangirala R.K., Westin S., Hoffmann A., Subramaniam S., David M., Rosenfeld M.G., Glass C.K. Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 2005, 122(5):707-721.
27. Ong K.G., Leland J.M., Zeng K., Barrett G., Zourob M., Grimes C.A. A rapid highly-sensitive endotoxin detection system. Biosensors and Bioelectronics 2006, 21(12):2270-2274.
28. Pepys M.B., Hirschfield G.M., Tennent G.A., Gallimore J.R., Kahan M.C., Bellotti V., Hawkins P.N., Myers R.M., Smith M.D., Polara A., Cobb A.J.A., Ley S.V., Aquilina J.A., Robinson C.V., Sharif I., Gray G.A., Sabin C.A., Jenvey M.C., Kolstoe S.E., Thompson D., Wood S.P. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature 2006, 440(7088):1217-1221.
29. Rhee S.H., Hwang D. Murine TOLL-like receptor 4 confers lipopolysaccharide responsiveness as determined by activation of NF kappa B and expression of the inducible cyclooxygenase. Journal of Biological Chemistry 2000, 275(44):34035-34040.
30. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391(6662):79-82.
31. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998, 97(5):425-428.
32. Ridker P.M., Rifai N., Rose L., Buring J.E., Cook N.R. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. New England Journal of Medicine 2002, 347(20):1557-1565.
33. Seino Y., Ikeda U., Ikeda M., Yamamoto K., Misawa Y., Hasegawa T., Kano S., Shimada K. Interleukin-6 gene transcripts are expressed in human atherosclerotic lesions. Cytokine 1994, 6(1):87-91.
34. Singh U., Dasu M.R., Yancey P.G., Afify A., Devaraj S., Jialal I. Human C-reactive protein promotes oxidized low density lipoprotein uptake and matrix metalloproteinase-9 release in Wistar rats. Journal of Lipid Research 2008, 49(5):1015-1023.
35. Speidl W.S., Graf S., Hornykewycz S., Nikfardjam M., Niessner A., Zorn G., Wojta J., Huber K. High-sensitivity C-reactive protein in the prediction of coronary events in patients with premature coronary artery disease. American Heart Journal 2002, 144(3):449-455.
36. Sukovich D.A., Kauser K., Shirley F.D., DelVecchio V., Halks-Miller M., Rubanyi G.M. Expression of interleukin-6 in atherosclerotic lesions of male apo E-knockout mice: inhibition of 17β-estradiol. Arteriosclerosis, Thrombosis, and Vascular Biology 1998, 18(9):1498-1505.
37. Takeda K., Akira S. Toll-like receptors in innate immunity. International Immunology 2005, 17(1):1-14.
38. Tobias P., Curtiss L.K. Thematic review series: the immune system and atherogenesis. Paying the price for pathogen protection: toll receptors in atherogenesis. Journal of Lipid Research 2005, 46(3):404-411.
39. Verma S., Badiwala M.V., Weisel R.D., Li S.H., Wang C.H., Fedak P.W.M., Li R.K., Mickle D.A.G. C-reactive protein activates the nuclear factor-kappaB signal transduction pathway in saphenous vein endothelial cells: implications for atherosclerosis and restenosis. The Journal of Thoracic and Cardiovascular Surgery 2003, 126(6):1886-1891.
40. Verma S., Li S.H., Badiwala M.V., Weisel R.D., Fedak P.W.M., Li R.K., Dhillon B., Mickle D.A.G. Endothelin antagonism and interleukin-6 inhibition attenuate the proatherogenic effects of C-reactive protein. Circulation 2002, 105(16):1890-1896.
41. Verma S., Devaraj S., Jialal I. Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation 2006, 113(17):2135-2150.
42. Wang C.H., Li S.H., Weisel R.D., Fedak P.W.M., Dumont A.S., Szmitko P., Li R.-K., Mickle D.A.G., Verma S. C-reactive protein upregulates angiotensin type 1 receptors in vascular smooth muscle. Circulation 2003, 107(13):1783-1790.
43. Wassmann S., Stumpf M., Strehlow K., Schmid A., Schieffer B., Böhm M., Nickenig G. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circulation Research 2004, 94(4):534-541.
44. Welch J.S., Ricote M., Akiyama T.E., Gonzalez F.J., Glass C.K. PPARγ and PPARδ negatively regulate specific subsets of lipopolysaccharide and IFN-γ target genes in macrophages. Proceedings of the National Academy of Science of the United States of America 2003, 100(11):6712-6717.
45. Woollard K.J., Phillips D.C., Griffiths H.R. Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clinical and Experimental Immunology 2002, 130(2):256-262.
46. Yang X., Coriolan D., Murthy V., Schultz K., Golenbock D.T., Beasley D. Proinflammatory phenotype of vascular smooth muscle cells: role of efficient Toll-like receptor 4 signaling. American Journal of Physiology-Heart and Circulatory Physiology 2005, 289(3):H1069-H1076.
47. Yoneyama M., Suhara W., Fukuhara Y., Fukuda M., Nishida E., Fujita T. Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. The EMBO Journal 1998, 17(4):1087-1095.
48. Zambrano N., Minopoli G., de Candia P., Russo T. The Fe65 adaptor protein interacts through its PID1 domain with the transcription factor CP2/LSF/LBP1. Journal of Biological Chemistry 1998, 273(32):20128-20133.